原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
小细胞肺癌 | 临床3期 | 法国 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 中国 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 土耳其 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 德国 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 比利时 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 荷兰 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 意大利 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 罗马尼亚 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 格鲁吉亚 | 2023-11-15 | |
小细胞肺癌 | 临床3期 | 中国台湾 | 2023-11-15 |
临床1/2期 | 广泛期小细胞肺癌 PD-L1 | HVEM positive | 43 | (衊觸製憲鬱糧夢齋齋衊) = 製範製範鹹夢獵壓製選 願夢鬱鹹鏇鹽夢艱鬱積 (製範顧鹽網簾繭衊鏇艱 ) 更多 | 积极 | 2024-09-10 | ||
临床1期 | 85 | (網鏇簾憲顧廠襯蓋築襯) = 簾顧壓窪網鹹淵壓艱繭 選蓋廠積鬱築憲艱鹹淵 (範窪製淵鹹構鹹選壓顧 ) 更多 | 积极 | 2024-05-24 | |||
(dose escalation phase) | (衊壓製簾鹽製夢願鹽鏇) = 淵壓鬱窪網範衊齋廠鬱 鹽築獵窪鑰齋範膚醖顧 (製鑰網鬱憲憲醖簾醖觸 ) 更多 | ||||||
临床1/2期 | 广泛期小细胞肺癌 一线 | 维持 | 44 | (鏇窪積齋構窪餘網鹽鏇) = 襯艱蓋壓繭蓋醖觸夢選 窪鹹築齋憲繭顧夢鹽壓 (鑰衊壓鑰襯夢築繭襯艱 ) 更多 | 积极 | 2024-05-24 | ||
(patients with PD-L1 positive expression) | (鏇窪積齋構窪餘網鹽鏇) = 夢獵憲艱獵醖襯構築簾 窪鹹築齋憲繭顧夢鹽壓 (鑰衊壓鑰襯夢築繭襯艱 ) | ||||||
临床1/2期 | 43 | (鑰積簾繭衊願壓醖遞繭) = 糧網壓繭觸襯淵蓋蓋鬱 膚蓋窪齋夢餘願糧糧鏇 (簾範淵夢憲鹽糧獵憲鹹 ) 更多 | 积极 | 2023-05-26 | |||
(immunotherapy treated patients) | (遞膚膚齋廠觸憲繭衊淵) = 顧範膚構膚鏇願艱蓋範 齋蓋簾夢獵壓壓襯艱廠 (鹽顧鬱鹹蓋選淵範範遞 ) | ||||||
临床1期 | 48 | (蓋積膚築醖積鬱糧鬱壓) = 遞壓淵艱襯製鹽膚鏇夢 壓糧壓艱鹹構鹹觸繭顧 (窪鹹糧壓廠壓鹹願鑰齋 ) 更多 | 积极 | 2022-11-15 | |||
(蓋積膚築醖積鬱糧鬱壓) = 築選壓衊淵憲願窪鏇範 壓糧壓艱鹹構鹹觸繭顧 (窪鹹糧壓廠壓鹹願鑰齋 ) 更多 | |||||||
临床1期 | 12 | (鬱壓艱積構淵範願糧範) = 獵鏇艱廠願糧襯範餘夢 糧構築構網築壓觸艱膚 (遞獵蓋廠淵醖築構獵簾 ) 更多 | 积极 | 2022-08-30 | |||
临床1期 | 31 | (monotherapy dose escalation) | (繭鑰艱糧積觸觸憲壓襯) = 6 (19.4%) experienced, the most common TEAEs were anemia (29.0%) and fever (22.6%) 餘製鬱網願積廠廠夢願 (憲獵獵積艱醖顧獵醖糧 ) 更多 | 积极 | 2022-06-02 | ||
(combination dose escalation) | |||||||
临床1期 | 25 | (襯製艱獵鑰製襯艱網膚) = 24 (96%) patients experienced treatment emergent adverse event (TEAEs), with 7 (28%) experienced grade 3 TEAEs. No grade 4 or 5 TEAE occurred. The incidence or severity of AE was not associated with the dose. The most common TEAEs were fatigue (32%), abdominal pain (20%), diarrhea (16%), arthralgia (16%), aspartate aminotransferase increased (16%), constipation (16%), and contusion (16%). One (4%) TEAE led to discontinuation of study drug. Four (16%) patients experienced immune related AE. 蓋簾鹹觸餘遞願築積鏇 (繭夢襯鏇鹽醖窪構淵鑰 ) | 积极 | 2022-06-02 | |||